Tecfidera

Tecfidera is the brand name for dimethyl fumarate, an oral immunomodulatory agent widely used to support adults with relapsing forms of multiple sclerosis (MS), including relapsing‑remitting disease and active secondary progressive MS. It helps reduce the frequency of flare‑ups (“relapses”) and supports a slower rate of disability progression over time by influencing immune pathways linked to inflammation and cellular damage in the central nervous system.
The precise way dimethyl fumarate works is not fully understood, but it is believed to modulate immune responses and activate antioxidant pathways — such as the Nrf2 pathway — that help protect nerve cells from oxidative stress and immune‑mediated damage. This dual support may lead to fewer MRI‑visible lesions and reduced neurological deterioration.
Tecfidera is supplied in delayed‑release capsules taken orally, usually twice a day. Clinical data have shown that it can significantly lower the rate of relapses and reduce central nervous system lesion activity compared with placebo in large patient groups, making it a foundation therapy for many people with relapsing MS.
Common experiences with dimethyl fumarate include flushing (skin warmth or redness), gastrointestinal issues such as nausea, diarrhoea, and abdominal discomfort, and headache. These effects are often most pronounced early on and may lessen with continued use.
Less common but important responses relate to changes in immune cell counts, especially lymphocytes, which can affect infection risk, and rare neurological events linked to viral reactivation. Healthcare teams typically monitor blood counts and general health indicators regularly during ongoing use.
Used as part of a broader neurological support strategy — including routine imaging, lifestyle management, and follow‑up care — Tecfidera’s immune‑modulating action supports stability in relapsing MS and helps many people manage disease over the long term.